Statins impair antitumor effects of rituximab by inducing conformational changes of CD20.
<h4>Background</h4>Rituximab is used in the treatment of CD20+ B cell lymphomas and other B cell lymphoproliferative disorders. Its clinical efficacy might be further improved by combinations with other drugs such as statins that inhibit cholesterol synthesis and show promising antilymph...
Guardado en:
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8a6f737eb02e4bb2b26604dc216cc95b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|